ABEO Abeona Therapeutics Inc.

Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 8:30 a.m. ET. The Company will also participate in one-on-one investor meetings at the conference.

A live webcast of the fireside chat will be available on the Investors section of the Abeona website under "Events" at . The webcast will be archived for 30 days. Those interested in attending the fireside chat or requesting a one-on-one meeting with Abeona are encouraged to contact their Jefferies representative.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s lead clinical program is EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Abeona’s fully integrated cell and gene therapy cGMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and potential commercial production of AAV-based gene therapies. For more information, visit .



Investor and Media Contact:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
EN
22/09/2022

Underlying

ABEOAbeona Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abeona Therapeutics Inc.

 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and...

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates - Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - - U.S. launch on track and first ZEVASKYN patient treatment expected in 3Q 2025, momentum building with strong patient interest at qualified treatment centers and referrals, positive insurance coverage established with multiple national and regional payers - - $226M in ...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Na...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On July 30, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to 14 individuals hired by Abeona, which equity awards relate to, in the ...

August 1, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center...

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area - Lucile Packard Children’s Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 - - ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - CLEVELAND, July 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activati...

July 15, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Re...

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million Cash resources totaled approximately $225 million as of June 30, 2025 CLEVELAND, July 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million on June 27, 2025. Including net proceeds from the sale of the PRV, the Company reported that unaudited cash, cash equivalents, restricted cash and short-term investments as of June 30, 2025 were approxi...

July 2, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics ...

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised its option to license Abeona's patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases that re...

July 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch